This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Apr 4;99(7):496-7.

doi: 10.1093/jnci/djk129.

Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies

Dipen J Parekh, Donna P Ankerst, Ian M Thompson

PMID: 17405989
DOI: 10.1093/jnci/djk129

Editorial

Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies

Dipen J Parekh et al. J Natl Cancer Inst. 2007.

. 2007 Apr 4;99(7):496-7.

doi: 10.1093/jnci/djk129.

Authors

Dipen J Parekh, Donna P Ankerst, Ian M Thompson

PMID: 17405989
DOI: 10.1093/jnci/djk129

No abstract available

PubMed Disclaimer

Comment on

Prostate-specific antigen levels as a predictor of lethal prostate cancer.
Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, Holmberg L; Scandinavian Prostate Cancer Group Study No. 4. Fall K, et al. J Natl Cancer Inst. 2007 Apr 4;99(7):526-32. doi: 10.1093/jnci/djk110. J Natl Cancer Inst. 2007. PMID: 17405997

Similar articles

[Detection of prostate cancer: yes or no?].
Van Cangh PJ. Van Cangh PJ. Bull Mem Acad R Med Belg. 2006;161(3-4):159-69. Bull Mem Acad R Med Belg. 2006. PMID: 17172224 Review. French. No abstract available.
Assessing risk: does this patient have prostate cancer?
Carter HB. Carter HB. J Natl Cancer Inst. 2006 Apr 19;98(8):506-7. doi: 10.1093/jnci/djj155. J Natl Cancer Inst. 2006. PMID: 16622114 No abstract available.
Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity.
Heidenreich A. Heidenreich A. Eur Urol. 2008 Nov;54(5):976-7; discussion 978-9. doi: 10.1016/j.eururo.2008.06.077. Epub 2008 Jul 2. Eur Urol. 2008. PMID: 18640768 No abstract available.
What is the value of screening for prostate cancer in the US?
Albertsen PC. Albertsen PC. Nat Clin Pract Oncol. 2005 Nov;2(11):536-7. doi: 10.1038/ncponc0348. Nat Clin Pract Oncol. 2005. PMID: 16270077 No abstract available.
Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).
Kirby RS, Fitzpatrick JM, Irani J. Kirby RS, et al. BJU Int. 2009 Feb;103(4):441-5. doi: 10.1111/j.1464-410X.2008.08280.x. Epub 2009 Jan 9. BJU Int. 2009. PMID: 19154510 Review.

See all similar articles

Cited by

Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
National Cancer Institute Surveillance, Epidemiology, and End Results Prostate-Specific Antigen Working Group; Adamo MP, Boten JA, Coyle LM, Cronin KA, Lam CJ, Negoita S, Penberthy L, Stevens JL, Ward KC. National Cancer Institute Surveillance, Epidemiology, and End Results Prostate-Specific Antigen Working Group, et al. Cancer. 2017 Feb 15;123(4):697-703. doi: 10.1002/cncr.30401. Epub 2016 Oct 26. Cancer. 2017. PMID: 27783399 Free PMC article.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

5UO1CA86402/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information